PRESS RELEASE published on 11/08/2024 at 07:00, 1 year 4 months ago Inside Information / Other news releases Innate Pharma announces new preclinical data on IPH6501 and IPH4502 to be presented at SITC Annual Meeting 2024. Advances in immunotherapy reflected in drug development progress Drug Development Preclinical Data Immunotherapy Innate Pharma SITC Annual Meeting 2024
PRESS RELEASE published on 09/12/2024 at 13:09, 1 year 6 months ago Rapports financiers et d'audit semestriels/examens réduits / Rapport financier semestriel
BRIEF published on 06/17/2024 at 07:05, 1 year 9 months ago Innate Pharma dévoile des résultats prometteurs pour le SAR443579/IPH6101 dans des cancers du sang Sanofi Innate Pharma SAR443579 Leucémie Cancer Du Sang
BRIEF published on 06/17/2024 at 07:05, 1 year 9 months ago Innate Pharma reveals promising results for SAR443579/IPH6101 in blood cancers Sanofi Innate Pharma SAR443579 Leukemia Blood Cancer
PRESS RELEASE published on 06/17/2024 at 07:00, 1 year 9 months ago Informations privilégiées / Autres communiqués Innate Pharma présente de nouveaux résultats sur l'essai de phase 1/2 mené par Sanofi évaluant le NK Cell Engager SAR443579/IPH6101 dans divers cancers du sang lors du congrès annuel de l'EHA 2024 Étude De Phase 1/2 Innate Pharma NK Cell Engager SAR443579/IPH6101 Cancers Du Sang
PRESS RELEASE published on 06/17/2024 at 07:00, 1 year 9 months ago Inside Information / Other news releases Innate Pharma shares updated results from the Sanofi developed blood cancer Phase 1/2 SAR443579/IPH6101 trial, showing promising clinical efficacy and safety in patients with R/R AML Sanofi Innate Pharma Blood Cancer NK Cell Engager Phase 1/2 Trial
BRIEF published on 05/28/2024 at 07:05, 1 year 9 months ago Innate Pharma annonce sa participation à de prochaines conférences investisseurs Immunothérapie Santé Conférences Investisseurs Innate Pharma Biotechnologies
BRIEF published on 05/28/2024 at 07:05, 1 year 9 months ago Innate Pharma announces its participation in upcoming investor conferences Biotechnology Investor Conferences Immunotherapy Health Innate Pharma
PRESS RELEASE published on 05/28/2024 at 07:00, 1 year 9 months ago Informations privilégiées / Autres communiqués Innate Pharma annonce sa participation à des conférences investisseurs mondiales à venir. Détails des conférences et objectif de la société biotechnologique axée sur les immunothérapies contre le cancer Biotechnologie Immunothérapie Cancer Conférences Investisseurs Innate Pharma
BRIEF published on 05/23/2024 at 22:05, 1 year 10 months ago Résultats de l'Assemblée Générale Mixte d'Innate Pharma Assemblée Générale Conseil De Surveillance Innate Pharma Résultats De Vote
Published on 03/27/2026 at 08:05, 59 minutes ago Battery X Metals Announces Corporate Awareness Engagements
Published on 03/26/2026 at 23:00, 10 hours 4 minutes ago FutureGen Industries Announces Closing of Debt Settlement
Published on 03/26/2026 at 22:05, 10 hours 59 minutes ago BlackBerry to Announce Fourth Quarter and Fiscal Year 2026 Results on April 9, 2026
Published on 03/26/2026 at 22:00, 11 hours 4 minutes ago Clean Air Metals Receives Provincial Funding and Provides Update on the Thunder Bay North Project
Published on 03/26/2026 at 22:00, 11 hours 4 minutes ago Green Bridge Metals Reports Visible Copper Sulfide Mineralization in Initial 2026 Titac Drilling, Duluth Complex Minnesota
Published on 03/27/2026 at 08:00, 1 hour 4 minutes ago ENERGISME: Des fonds investissent 5 M€ dans Energisme pour le développement de Loamics, sa filiale santé
Published on 03/27/2026 at 07:45, 1 hour 19 minutes ago Pyrum Innovations AG publishes preliminary results for financial year 2025
Published on 03/27/2026 at 07:30, 1 hour 33 minutes ago DKSH Performance Materials Acquires AIC Ingredients, a Leading Customized Food Solutions Manufacturer in Malaysia
Published on 03/27/2026 at 07:30, 1 hour 33 minutes ago Haier Celebrates Excellence in Paris With New Smart Home Portfolio
Published on 03/27/2026 at 07:00, 2 hours 4 minutes ago WEB SA - CONVOCATION ASSEMBLEE GENERALE ORDINAIRE EXERCICE 2025 - 28/04/2026
Published on 03/26/2026 at 18:17, 14 hours 47 minutes ago Eiffage se renforce au capital de Getlink et porte sa participation à 29,40 % du capital
Published on 03/26/2026 at 18:17, 14 hours 47 minutes ago Eiffage strengthens its position in Getlink capital
Published on 03/26/2026 at 18:00, 15 hours 4 minutes ago Arrêté des comptes au 31 décembre 2025 et perspectives 2026
